Carla Morgado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Carla Morgado has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Isaura Tavares
Unit of Experimental Biology, Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
11 shared publications - Patrícia Pereira-Terra
Departments of Surgery, Division of Pediatric Surgery, Pediatrics & Child Health and Physiology & Pathophysiology (Adjunct), University of Manitoba and Children's Hospital Research Institute of Manitoba, Biology of Breathing Theme, Winnipeg, Manitoba, Canada
6 shared publications I. Tavares
4 shared publications- Filipa Pinto-Ribeiro
Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus of Gualtar, Braga 4710-057, Portugal; ICVS/3 B's - PT Government Associate Laboratory, Braga, Guimarães, Portugal
2 shared publications P. Pereira‐Terra
2 shared publicationsA. Mirandan
1 shared publication
Latest Publications
- 1 October 2014
- Published by Elsevier in Neuropharmacology
- Vol. 85, 151-157
“Hotheaded”: The role OF TRPV1 in brain functions
- 1 October 2014
- Published by Elsevier in Neuropharmacology
- Vol. 85, 151-157
“Hotheaded”: The role OF TRPV1 in brain functions
- 1 July 2013
- Published by Elsevier in Brain Research Bulletin
- Vol. 96, 39-44
Pronociceptive changes in the activity of rostroventromedial medulla (RVM) pain modulatory cells in the streptozotocin-diabetic rat
- 1 July 2013
- Published by Elsevier in Brain Research Bulletin
- Vol. 96, 39-44
Pronociceptive changes in the activity of rostroventromedial medulla (RVM) pain modulatory cells in the streptozotocin-diabetic rat
- 1 August 2012
- Published by Oxford University Press (OUP) in Microscopy and Microanalysis
- Vol. 18 (S5) , 5-6
EGCG Prevents the Loss of Pontine Noradrenergic Neurons Induced by Diabetes: A Role in Diabetic Neuropathic Pain
Diabetes is a major health problem with an alarming increasing prevalence, and is the most frequent cause of neuropathy worldwide. Neuropathy affects 50–60% of diabetic patients, being a major life-quality impairment for a quarter of these patients. Diabetic neuropathic pain (DNP) is characterized by spontaneous pain, mechanical hyperalgesia and tactile allodynia and is accompanied by functional and neurochemical changes at the peripheral nerves, spinal cord and supraspinal pain control areas. Regarding the effects of diabetic neuropathy in the central somatossensory system, it was shown that streptozotocin (STZ)-diabetic rats present spontaneous hyperactivity and hyperexcitability of spinal nociceptive neurons, which may be subserving the exacerbated pain responses. The spinal functional changes and pain may be due to increased peripheral input(2), changes in spinal nociceptive modulatory mechanisms and altered supraspinal descending pain modulation. Noradrenergic descending pain modulation seems to be impaired since STZ-diabetic rats present decreased numbers of noradrenergic neurons at the A5 and A7 pontine cell groups, along with lower levels of noradrenaline at the spinal cord and higher behavioral responses to pain. This is consistent with the strong noradrenergic projection from A5 and A7 neurons to the spinal dorsal horn and the modulation of nociceptive transmission by local release of noradrenaline. The mechanisms underlying the decrease in noradrenergic neurons in the brainstem during diabetes remain unclear. Our recent findings that diabetes induces oxidative stress damage in neurons from those areas, lead us to hypothesize that it may contribute to their loss. Thereafter, with the present study we aimed to evaluate the effects of Epigallocathechin Gallate (EGCG), a potent antioxidant present in green tea, on spinal noradrenaline levels, on A5 and A7 noradrenergic neurons and on behavioral pain responses of STZ-diabetic rats.
- 1 August 2012
- Published by Oxford University Press (OUP) in Microscopy and Microanalysis
- Vol. 18 (S5) , 5-6
EGCG Prevents the Loss of Pontine Noradrenergic Neurons Induced by Diabetes: A Role in Diabetic Neuropathic Pain
Diabetes is a major health problem with an alarming increasing prevalence, and is the most frequent cause of neuropathy worldwide. Neuropathy affects 50–60% of diabetic patients, being a major life-quality impairment for a quarter of these patients. Diabetic neuropathic pain (DNP) is characterized by spontaneous pain, mechanical hyperalgesia and tactile allodynia and is accompanied by functional and neurochemical changes at the peripheral nerves, spinal cord and supraspinal pain control areas. Regarding the effects of diabetic neuropathy in the central somatossensory system, it was shown that streptozotocin (STZ)-diabetic rats present spontaneous hyperactivity and hyperexcitability of spinal nociceptive neurons, which may be subserving the exacerbated pain responses. The spinal functional changes and pain may be due to increased peripheral input(2), changes in spinal nociceptive modulatory mechanisms and altered supraspinal descending pain modulation. Noradrenergic descending pain modulation seems to be impaired since STZ-diabetic rats present decreased numbers of noradrenergic neurons at the A5 and A7 pontine cell groups, along with lower levels of noradrenaline at the spinal cord and higher behavioral responses to pain. This is consistent with the strong noradrenergic projection from A5 and A7 neurons to the spinal dorsal horn and the modulation of nociceptive transmission by local release of noradrenaline. The mechanisms underlying the decrease in noradrenergic neurons in the brainstem during diabetes remain unclear. Our recent findings that diabetes induces oxidative stress damage in neurons from those areas, lead us to hypothesize that it may contribute to their loss. Thereafter, with the present study we aimed to evaluate the effects of Epigallocathechin Gallate (EGCG), a potent antioxidant present in green tea, on spinal noradrenaline levels, on A5 and A7 noradrenergic neurons and on behavioral pain responses of STZ-diabetic rats.
- Open Access
- 1 July 2012
- Published by S. Karger AG in Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo
- Vol. 7 (2) , 87
CO068. A ADMINISTRAÇÃO DE EGCG PREVINE O STRESS OXIDATIVO E A PERDA NEURONAL NO RVM DE RATOS COM NEUROPATIA DIABÉTICA DOLOROSA
- 1 July 2012
- Published by S. Karger AG in Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo
- Vol. 7 (2) , 87
Open AccessCO068. A ADMINISTRAÇÃO DE EGCG PREVINE O STRESS OXIDATIVO E A PERDA NEURONAL NO RVM DE RATOS COM NEUROPATIA DIABÉTICA DOLOROSA
- 1 July 2011
- Published by Elsevier in Neurobiology of Disease
- Vol. 43 (1) , 275-284
Changes in serotoninergic and noradrenergic descending pain pathways during painful diabetic neuropathy: The preventive action of IGF1
- 1 July 2011
- Published by Elsevier in Neurobiology of Disease
- Vol. 43 (1) , 275-284
Changes in serotoninergic and noradrenergic descending pain pathways during painful diabetic neuropathy: The preventive action of IGF1
- 17 March 2011
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (8) , 736-741
α ‐Lipoic acid normalizes nociceptive neuronal activity at the spinal cord of diabetic rats
Aim: To evaluate the effects of antioxidant treatment of streptozotocin (STZ)‐diabetic rats with α ‐lipoic acid ( α ‐LA) in neuronal and microglial activation at the spinal cord, an important relay station of nociceptive transmission. Because of the role of the potassium chloride co‐transporter 2 (KCC2) in neuronal activation at the spinal cord and the influence of microglia in KCC2 expression, we also evaluated the effects of α ‐LA in KCC2 expression at the spinal cord. Methods: Four weeks after STZ injection, the rats received daily intraperitoneal injections of α ‐LA (100 mg/kg), during 2 weeks. Mechanical nociception was evaluated before and after α ‐LA treatment. Spinal cords were immunoreacted against 8‐OH‐dG (marker of oxidative stress damage), Fos (marker of neuronal activation) and CD11b (marker of microglia). KCC2 expression was evaluated by immunohistochemistry and western blotting. Results: Treatment with α ‐LA decreased the 8‐OH‐dG and Fos expressions to controls' levels, but did not affect CD11b. Treatment with α ‐LA alleviated mechanical hyperalgesia and partially corrected KCC2 expression. Conclusions: This study shows that neuronal hyperactivity at the spinal cord of STZ‐diabetic rats can be corrected by α ‐LA, which may account for alleviation of mechanical hyperalgesia. These effects are probably partially mediated by KCC2, but are independent from microglia.
- 17 March 2011
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (8) , 736-741
α ‐Lipoic acid normalizes nociceptive neuronal activity at the spinal cord of diabetic rats
Aim: To evaluate the effects of antioxidant treatment of streptozotocin (STZ)‐diabetic rats with α ‐lipoic acid ( α ‐LA) in neuronal and microglial activation at the spinal cord, an important relay station of nociceptive transmission. Because of the role of the potassium chloride co‐transporter 2 (KCC2) in neuronal activation at the spinal cord and the influence of microglia in KCC2 expression, we also evaluated the effects of α ‐LA in KCC2 expression at the spinal cord. Methods: Four weeks after STZ injection, the rats received daily intraperitoneal injections of α ‐LA (100 mg/kg), during 2 weeks. Mechanical nociception was evaluated before and after α ‐LA treatment. Spinal cords were immunoreacted against 8‐OH‐dG (marker of oxidative stress damage), Fos (marker of neuronal activation) and CD11b (marker of microglia). KCC2 expression was evaluated by immunohistochemistry and western blotting. Results: Treatment with α ‐LA decreased the 8‐OH‐dG and Fos expressions to controls' levels, but did not affect CD11b. Treatment with α ‐LA alleviated mechanical hyperalgesia and partially corrected KCC2 expression. Conclusions: This study shows that neuronal hyperactivity at the spinal cord of STZ‐diabetic rats can be corrected by α ‐LA, which may account for alleviation of mechanical hyperalgesia. These effects are probably partially mediated by KCC2, but are independent from microglia.
- 27 December 2010
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (2) , 150-159
Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia‐induced changes in the expression of the potassium chloride co‐transporter 2 (KCC2) at the spinal cord
Aim: Neuronal hyperactivity at the spinal cord during mechanical hyperalgesia induced by diabetes may result from a decrease in the local expression of the potassium chloride co‐transporter 2 (KCC2), which shifts the action of the neurotransmitter γ ‐amminobutiric acid (GABA) from inhibitory to excitatory. In this study, we evaluated the effects of spinal microglia inhibition or brain‐derived neurotrophic factor (BDNF) blockade on KCC2 expression, spinal neuronal activity and mechanically induced pain responses of streptozotocin (STZ)‐diabetic rats. Methods: Four weeks after induction of diabetes, the STZ‐diabetic rats received daily intrathecal injections, for 3 days, of minocycline (microglia inhibitor), TrkB/Fc (BDNF sequester) or saline. Behavioural responses to mechanical nociceptive stimulation of STZ‐diabetic rats were evaluated by the Randall‐Selitto test. The lumbar spinal cord was immunoreacted against the Fos protein (marker of neuronal activation) or KCC2, which was also quantified by western blotting. BDNF levels at the spinal cord were quantified by an enzyme‐linked immunosorbent assay (ELISA). Results: Minocycline treatment reversed the mechanical hyperalgesia, increased Fos expression and decreased the KCC2 expression detected in STZ‐diabetic rats to control levels. Treatment with TrkB/Fc was less effective, inducing moderate effects in mechanical hyperalgesia and Fos expression and only a partial correction of KCC2 expression. BDNF levels were not increased in STZ‐diabetic rats. Conclusions: This study demonstrates that the microglial activation at the spinal cord contributes to mechanical hyperalgesia and spinal neuronal hyperactivity induced by diabetes, apparently by regulating the KCC2 expression. These effects do not seem to be mediated by BDNF, which is an important difference from other chronic pain conditions. New targets directed to prevent spinal microglia activation should be considered for the treatment of mechanical hyperalgesia induced by diabetes.
- 27 December 2010
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (2) , 150-159
Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia‐induced changes in the expression of the potassium chloride co‐transporter 2 (KCC2) at the spinal cord
Aim: Neuronal hyperactivity at the spinal cord during mechanical hyperalgesia induced by diabetes may result from a decrease in the local expression of the potassium chloride co‐transporter 2 (KCC2), which shifts the action of the neurotransmitter γ ‐amminobutiric acid (GABA) from inhibitory to excitatory. In this study, we evaluated the effects of spinal microglia inhibition or brain‐derived neurotrophic factor (BDNF) blockade on KCC2 expression, spinal neuronal activity and mechanically induced pain responses of streptozotocin (STZ)‐diabetic rats. Methods: Four weeks after induction of diabetes, the STZ‐diabetic rats received daily intrathecal injections, for 3 days, of minocycline (microglia inhibitor), TrkB/Fc (BDNF sequester) or saline. Behavioural responses to mechanical nociceptive stimulation of STZ‐diabetic rats were evaluated by the Randall‐Selitto test. The lumbar spinal cord was immunoreacted against the Fos protein (marker of neuronal activation) or KCC2, which was also quantified by western blotting. BDNF levels at the spinal cord were quantified by an enzyme‐linked immunosorbent assay (ELISA). Results: Minocycline treatment reversed the mechanical hyperalgesia, increased Fos expression and decreased the KCC2 expression detected in STZ‐diabetic rats to control levels. Treatment with TrkB/Fc was less effective, inducing moderate effects in mechanical hyperalgesia and Fos expression and only a partial correction of KCC2 expression. BDNF levels were not increased in STZ‐diabetic rats. Conclusions: This study demonstrates that the microglial activation at the spinal cord contributes to mechanical hyperalgesia and spinal neuronal hyperactivity induced by diabetes, apparently by regulating the KCC2 expression. These effects do not seem to be mediated by BDNF, which is an important difference from other chronic pain conditions. New targets directed to prevent spinal microglia activation should be considered for the treatment of mechanical hyperalgesia induced by diabetes.
- 1 August 2010
- Published by Wiley in European journal of pain
- Vol. 14 (7) , 693-699
Neuronal hyperactivity at the spinal cord and periaqueductal grey during painful diabetic neuropathy: Effects of gabapentin
Painful diabetic neuropathy may be due to impairments in descending modulation of nociceptive transmission at the spinal cord. In the present study, streptozotocin diabetic rats (STZ rats) with neuropathic symptoms (mechanical hypersensitivity) were used to perform a time‐course evaluation of neuronal activity at the spinal dorsal horn and at the periaqueductal grey matter (PAG), a major brainstem area of pain modulation. The expression of Fos protein, a marker of nociceptive activation, progressively increased at the spinal dorsal horn at 4 and 10 weeks. At the PAG, increases in Fos expression were detected until the 4th week, with a reversal to baseline values at 10 weeks in all areas except the ventrolateral PAG. Co‐localisation of Fos with NeuN ascertained the neuronal nature of Fos‐expressing cells at the spinal cord and PAG. Four weeks after diabetes induction, the effects of gabapentin (i.p. injection of 50 mg/kg, daily during 3 days) were assessed. Gabapentin decreased Fos expression at the spinal cord and PAG and reversed mechanical hypersensitivity. The present study shows that diabetic neuropathy is accompanied by a progressive increase of the spontaneous neuronal activity at the spinal cord. Changes in descending modulation of nociceptive transmission from the PAG are likely to occur during diabetic neuropathy, probably with exacerbation of facilitatory actions. The effects of gabapentin in reversing the behavioural signs of diabetic neuropathy and neuronal hyperactivity in the spinal cord and PAG reinforce the central causes of diabetic neuropathy and point to the central targets of the drug.
- 1 August 2010
- Published by Wiley in European journal of pain
- Vol. 14 (7) , 693-699
Neuronal hyperactivity at the spinal cord and periaqueductal grey during painful diabetic neuropathy: Effects of gabapentin
Painful diabetic neuropathy may be due to impairments in descending modulation of nociceptive transmission at the spinal cord. In the present study, streptozotocin diabetic rats (STZ rats) with neuropathic symptoms (mechanical hypersensitivity) were used to perform a time‐course evaluation of neuronal activity at the spinal dorsal horn and at the periaqueductal grey matter (PAG), a major brainstem area of pain modulation. The expression of Fos protein, a marker of nociceptive activation, progressively increased at the spinal dorsal horn at 4 and 10 weeks. At the PAG, increases in Fos expression were detected until the 4th week, with a reversal to baseline values at 10 weeks in all areas except the ventrolateral PAG. Co‐localisation of Fos with NeuN ascertained the neuronal nature of Fos‐expressing cells at the spinal cord and PAG. Four weeks after diabetes induction, the effects of gabapentin (i.p. injection of 50 mg/kg, daily during 3 days) were assessed. Gabapentin decreased Fos expression at the spinal cord and PAG and reversed mechanical hypersensitivity. The present study shows that diabetic neuropathy is accompanied by a progressive increase of the spontaneous neuronal activity at the spinal cord. Changes in descending modulation of nociceptive transmission from the PAG are likely to occur during diabetic neuropathy, probably with exacerbation of facilitatory actions. The effects of gabapentin in reversing the behavioural signs of diabetic neuropathy and neuronal hyperactivity in the spinal cord and PAG reinforce the central causes of diabetic neuropathy and point to the central targets of the drug.
- 1 September 2009
- Published by Wiley in European journal of pain
- Vol. 13 (S1)
579 ADMINISTRATION OF LOW DOSES OF INSULIN AND IGF‐1 IMPROVES PAINFUL DIABETIC NEUROPATHY IN STREPTOZOTOCIN‐DIABETIC RATS
- 1 September 2009
- Published by Wiley in European journal of pain
- Vol. 13 (S1)
579 ADMINISTRATION OF LOW DOSES OF INSULIN AND IGF‐1 IMPROVES PAINFUL DIABETIC NEUROPATHY IN STREPTOZOTOCIN‐DIABETIC RATS